Company news
Medmira Inc. (TSXV:MIR) news
Medmira Inc. news releases on 6ix. Latest, Jun 30, 2026: MedMira Reports Third Quarter Results FY2026
Press releases & updates
MedMira Reports Third Quarter Results FY2026
June 29, 2026
MedMira Reports First Quarter Results FY2026
December 30, 2025
MedMira Reports FY2025 Fourth Quarter and Year End Financial Results
November 28, 2025
Health Canada Approves MedMira's Reveal(R) Rapid TP Test - Urgent New Tool In The Battle Against Syphilis
August 26, 2025
MedMira Announces Launch of Clinical Trial for Its Multiplo(R) TP/HIV Self-Test in Canada
July 7, 2025
MedMira Reports Second Quarter Results FY2025
June 30, 2025
MedMira Inc. and Lovell Announce Partnership to Increase Access to Reveal(R) G4 HIV-1/2 rapid test for VA, Department of Defense
April 17, 2025
MedMira Announces Partnership with MediGroup Physician Services in the United States
February 27, 2025
MedMira Announces Exclusive Distribution Agreement with Trimedic Inc. for Canada
February 25, 2025
MedMira Receives Investigational Testing Authorizations for Multiplo(R) TP/HIV Self-Test and Non-Professional Use Applications
January 21, 2025
MedMira Receives Health Canada Approval for Its Reveal(R) G4 Rapid HIV-1/2 Test for Point-of-Care Use
January 14, 2025
MedMira Receives Investigational Testing Authorization for its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test
January 9, 2025
MedMira Reports First Quarter Results FY2025
December 30, 2024
TSX Venture Exchange Stock Maintenance Bulletins
December 24, 2024
Canadian Investment Regulatory Organization Trade Resumption - MIR
December 24, 2024
MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV
December 24, 2024
Canadian Investment Regulatory Organization Trading Halt - MIR
December 24, 2024
MedMira Reports FY2024 Fourth Quarter and Year End Financial Results
November 28, 2024
MedMira Announces the appointment of Vice President of Commercial Operations
October 3, 2024
Clinical Trials to get Underway with Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test - A Potential Game Changer to Address Syphilis Health Crisis in Canada
August 13, 2024
MedMira Reports Third Quarter Results FY2024
July 2, 2024
MedMira Announces the Hire of Vice President of Business Development
April 30, 2024
MedMira Reports Second Quarter Results FY2024
April 1, 2024
MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System
March 13, 2024
CORRECTION BY SOURCE: Corporate Update on Clinical Evaluation of MedMira's Products
February 1, 2024
Corporate Update on Clinical Evaluation of MedMira's Products
February 1, 2024
MedMira Reports First Quarter Results FY2024
December 29, 2023
U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test
December 13, 2023
MedMira Reports FY2023 Fourth Quarter and Year End Financial Results
November 28, 2023
Update on MedMira's Regulatory Path in Canada and the USA
September 27, 2023
Progress Update on Securities
August 30, 2023
MedMira Reports Third Quarter Results FY2023
June 29, 2023
MedMira Reports Second Quarter Results FY2023
April 3, 2023
Update on MedMira's Reveal TP (Syphilis) Clinical Trials in Canada
March 14, 2023
MedMira enters into Partnership with Maternova for USA and Latin America
February 21, 2023
MedMira Enters into Partnership with Maternova for USA and Latin America
February 20, 2023
MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test
January 11, 2023
Point-of-Care Diagnostic for Trichomonas Vaginalis Based on MedMira's RVF Technology(R)
January 3, 2023
MedMira Reports First Quarter Results FY2023
December 30, 2022
MedMira Introduces VYRA TriDemic
December 29, 2022
MedMira Reports FY2021 Fourth Quarter and Year End Financial Results
November 29, 2022
MedMira Receives CE Mark for Its VYRA(TM) COVID-19 Antigen Test
October 14, 2022
MedMira provides Progress Update
October 3, 2022
MedMira Strengthens and Expands Board
July 14, 2022
MedMira Reports Third Quarter Results FY2022
June 28, 2022
MedMira Receives Patent for its Unique Quantitative Diagnostic System
June 6, 2022
MedMira provides an update on the new In Vitro Diagnostic Medical Devices Regulation (IVDR) in the European Market
May 27, 2022
MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test
May 12, 2022
MedMira receives the CE mark for its Reveal TP (Syphilis) and starts clinical trials in Canada
March 10, 2022
MedMira receives the CE mark for its Reveal® TP (Syphilis) and starts clinical trials in Canada
March 9, 2022